Colorectal Cancer Metastatic
Conditions
Brief summary
Cytoreductive surgery with intraperitoneal chemotherapy is one of the most important treatments for patients with colorectal cancer and peritoneal metastasis. For the best survival rates, complete removal of all metastatic lesions is the most important part of treatment, and various surgical procedures are required for the complete cytoreduction. Therefore, the postoperative morbidity rates are higher than those of localized colon cancer surgeries and patients can experience a prolonged recovery period and deterioration of physical activities over a long period. The aim of this study is to investigate the change of quality of life after cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer.
Interventions
Cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer or pseudomyxoma peritonei. Either early postoperative intraperitoneal chemotherapy (EPIC) or hyperthermic intraperitoneal chemotherapy (HIPEC) is used for intraperitoneal chemotherapy.
Sponsors
Kyungpook National University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Colorectal cancer peritoneal metastasis * Pseudomyxoma peritonei * ECOG (Eastern Cooperative Oncology Group) performance status 0-3 * Normal bone marrow, kidney, and liver function * Patient must sign and date the informed consent
Exclusion criteria
* Palliative surgery * Palliative intraperitoneal chemotherapy * Psychotic disorder * Drug abuser
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Brief pain inventory (BPI) | Changes from baseline pain scores at postoperative 12 months | Pain recovery after cytoreductive surgery and intraperitoneal chemotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| European Organisation for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ)-C30 | preoperative, postoperative 3 months, postoperative 6 months, postoperative 12 months, postoperative 24 months | Qualify of life questionnaire for cancer patients |
| EORTC QLQ for colorectal cancer | preoperative, postoperative 3 months, postoperative 6 months, postoperative 12 months, postoperative 24 months | Quality of life questionnaire for patients with colorectal cancer |
| Short-form(SF)-36 | preoperative, postoperative 3 months, postoperative 6 months, postoperative 12 months, postoperative 24 months | Global measure of health-related quality of life |
| Postoperative morbidity | 90 days after surgery | Incidence and degree of surgical and medical complications after surgery |
| Postoperative mortality | 90 days after surgery | Incidence of postoperative mortality |
| Postoperative recovery | 150 days after surgery | Duration of hospital stay after surgery |
| Brief pain inventory (BPI) | preoperative, postoperative 3 months, postoperative 6 months, postoperative 24 months | Pain recovery after cytoreductive surgery and intraperitoneal chemotherapy |
Countries
South Korea
Contacts
PRINCIPAL_INVESTIGATORSoo Yeun Park, MD
Colorectal Cancer Center, Kyungpook National University Chilgok Hospital
Outcome results
None listed